NCT00804934已完成不适用
Phase II Study Intravitreally Admininstered Ranibizumab in 50 Subjects With AMD Having Received at Least 3 Doses of Intermittent Anti-VEGF Therapy in the Preceding 18 Months
Retina Institute of Hawaii1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2008年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Mean change in visual acuity at 6 and 12 months
研究概览
简要总结
The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.
详细描述
To determine mean change in visual acuity at 6 and 12 months
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Ability to provide written informed consent and comply with study assessments for the full duration of the study
- •Age greater then and equal 50 years
- •Patients with active neovascular AMD
- •Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months
- •If the patient has bilateral disease and qualifies for the study, both eyes may be included
排除标准
- •Subjects who meet any of the following criteria will be excluded from this study:
- •Pregnancy or lactation
- •Premenopausal women not using adequate contraception.
- •Participation in another simultaneous medical investigation
研究组 & 干预措施
0
干预措施: Lucentis (Drug)
结局指标
主要结局
Mean change in visual acuity at 6 and 12 months
时间窗: one year
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Effect of Intravitreal Anti-VEGF on Retinal Vessels DiameterAge Related Macular DegenerationNCT01626339University of Malaya30
Unknown
3 期
Study of the Long-Term Effect of Frequent Anti-VEGF Dosing on Retinal Function in Patients With Neovascular AMDElectrophysiologyNCT00533689Tel-Aviv Sourasky Medical Center2,008
已完成
2 期
Phase II/III Study of Anti-VEGF in Neovascular AMDMacular DegenerationChoroidal NeovascularizationNCT00021736Eyetech Pharmaceuticals540
已完成
2 期
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)Diabetic RetinopathyNCT00336323Jaeb Center for Health Research121
Unknown
3 期
Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)RanibizumabDiabetic RetinopathyNCT03452657Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine118